Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.35 |
| ▸ | MAT2A | P31153 | 4/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.33 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25354173 | 0.88 | NR1D1 (0.34) | NR1D1MAT2APDE2ACASRACACB | |
| SCHEMBL29494685 | 0.84 | NLRP3 (0.52) | NLRP3POLB | |
| SCHEMBL25357509 | 0.81 | NLRP3 (0.38) | NLRP3MAT2APDE2A | |
| SCHEMBL25357804 | 0.77 | PRMT5 (0.39) | PDE2A | |
| SCHEMBL25357255 | 0.74 | NLRP3 (0.37) | NLRP3SSTR5 | |
| SCHEMBL25356266 | 0.71 | PTGDR2 (0.40) | — | |
| SCHEMBL29492104 | 0.71 | NLRP3 (0.75) | NLRP3MAT2AEEDRBBP4SUZ12 | |
| SCHEMBL29494686 | 0.70 | MAT2A (0.37) | NR1D1MAT2APDE2ARBP4ACSS2 | |
| SCHEMBL25354967 | 0.70 | ADORA2A (0.33) | CASR | |
| SCHEMBL25356382 | 0.68 | NLRP3 (0.49) | NLRP3EEDRBBP4SUZ12EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217346-B1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-02 | — | — | EP | disclosed |
| US-20230391756-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-07 | — | — | US | disclosed |
| EP-4217346-A1 | NEW COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022063876-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391756-A1 | NEW COMPOUND | NLRP3, NLRP1, IL1R1 | NLRP3 1/4885NR1D1 142/4885MAT2A 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.